FDA approves Ironwood's constipation drug Linzess for pediatric use

The US Food and Drug Administration has expanded its approval of Ironwood Pharmaceuticals' (NASDAQ:IRWD) drug Linzess to include the treatment of functional constipation in children and teens.

Linzess was already approved to treat adults with irritable bowel syndrome with constipation or idiopathic constipation. The drug is marketed by Ironwood and AbbVie (NYSE:ABBV) in the US.

Ironwood said the drug is the first FDA-approved prescription medication to treat children aged six to 17 with functional constipation, according to the company.

More on Ironwood:

Ironwood (IRWD) Presents At Life Sciences Conference -Slideshow

Ironwood falls 15% on deal to buy VectivBio for $17/share cash

Ironwood Pharmaceuticals gains amid activist speculation

Ironwood Pharmaceuticals to eliminate COO role